Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

por Pope, Janet E., Keystone, Edward, Jamal, Shahin, Wang, Lisy, Fallon, Lara, Woolcott, John, Lazariciu, Irina, Chapman, Douglass, Haraoui, Boulos
Publicado 2019

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

por Panaccione, Remo, Abreu, Maria T., Lazariciu, Irina, Mundayat, Rajiv, Lawendy, Nervin, Salese, Leonardo, Woolcott, John C., Sands, Bruce E., Chaparro, María
Publicado 2022

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

por Burmester, Gerd R., Coates, Laura C., Cohen, Stanley B., Tanaka, Yoshiya, Vranic, Ivana, Nagy, Edward, Lazariciu, Irina, Chen, All-shine, Kwok, Kenneth, Fallon, Lara, Kinch, Cassandra
Publicado 2023

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

por Wollenhaupt, Jürgen, Lee, Eun-Bong, Curtis, Jeffrey R., Silverfield, Joel, Terry, Ketti, Soma, Koshika, Mojcik, Chris, DeMasi, Ryan, Strengholt, Sander, Kwok, Kenneth, Lazariciu, Irina, Wang, Lisy, Cohen, Stanley
Publicado 2019

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

por van Vollenhoven, Ronald, Lee, Eun Bong, Strengholt, Sander, Mojcik, Christopher, Valdez, Hernan, Krishnaswami, Sriram, Biswas, Pinaki, Lazariciu, Irina, Hazra, Anasuya, Clark, James D., Hodge, Jennifer, Wang, Lisy, Choy, Ernest
Publicado 2019